Kineta Total Liabilities and Share Holders Equity 2014-2024 | KANT
Kineta total liabilities and share holders equity from 2014 to 2024. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.
Kineta Annual Total Liabilities and Share Holders Equity
(Millions of US $) |
| 2023 |
$10 |
| 2022 |
$17 |
| 2021 |
$13 |
| 2020 |
$115 |
| 2019 |
$18 |
| 2018 |
$136 |
| 2017 |
$79 |
| 2016 |
$91 |
| 2015 |
$19 |
| 2014 |
$12 |
| 2013 |
$7 |
Kineta Quarterly Total Liabilities and Share Holders Equity
(Millions of US $) |
| 2024-06-30 |
$1 |
| 2024-03-31 |
$2 |
| 2023-12-31 |
$10 |
| 2023-09-30 |
$11 |
| 2023-06-30 |
$18 |
| 2023-03-31 |
$13 |
| 2022-12-31 |
$17 |
| 2022-09-30 |
$10 |
| 2022-06-30 |
$15 |
| 2022-03-31 |
$32 |
| 2021-12-31 |
$13 |
| 2021-09-30 |
$70 |
| 2021-06-30 |
$81 |
| 2021-03-31 |
$92 |
| 2020-12-31 |
$115 |
| 2020-09-30 |
$54 |
| 2020-06-30 |
$64 |
| 2020-03-31 |
$73 |
| 2019-12-31 |
$18 |
| 2019-09-30 |
$94 |
| 2019-06-30 |
$106 |
| 2019-03-31 |
$123 |
| 2018-12-31 |
$136 |
| 2018-09-30 |
$64 |
| 2018-06-30 |
$79 |
| 2018-03-31 |
$82 |
| 2017-12-31 |
$79 |
| 2017-09-30 |
$61 |
| 2017-06-30 |
$62 |
| 2017-03-31 |
$75 |
| 2016-12-31 |
$91 |
| 2016-09-30 |
$104 |
| 2016-06-30 |
$45 |
| 2016-03-31 |
$52 |
| 2015-12-31 |
$19 |
| 2015-09-30 |
$0 |
| 2015-06-30 |
$0 |
| 2015-03-31 |
$0 |
| 2014-12-31 |
$12 |
| 2013-12-31 |
$7 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
